Mission Therapeutics Ltd. CEO Anker Lundemose speaks to Scrip senior editor Lucie Ellis about the company's clinical strategy that will see its first compound enter human trials in the first half 2019.
As the chief executive of a UK biotech, Lundemose also highlights his concerns around Brexit – particularly how changes could...








